Last updated: March 20, 2026
What is the scope of patent KR102421388?
Patent KR102421388 covers a novel pharmaceutical composition designed for therapeutic use. The patent claims broadly encompass a specific class of compounds, their pharmaceutical formulations, and associated methods of treatment. The scope is characterized by:
- A molecular structure specification for the active ingredient, including optional substitutions at designated positions.
- Composition claims that include excipients and carriers compatible with the active compound.
- Method claims that involve administering the composition for treating specific diseases.
This patent aims to protect the chemical structure and its application in disease management, primarily targeting inflammatory, neurodegenerative, or oncological indications.
What are the main claims of KR102421388?
The patent contains multiple claims categorized into independent and dependent claims.
Independent Claims:
-
Compound Claims: Patent claims the active compound with a defined chemical formula, including specific substituents at particular positions, for example:
"A compound having the chemical structure of formula I, wherein R1 and R2 are independently selected from hydrogen, halogen, or alkyl groups."
-
Pharmaceutical Composition Claims: Claims covering formulations comprising the compound alongside pharmaceutically acceptable carriers and excipients.
-
Method of Use: Claims to administering the composition for treating diseases such as Alzheimer's disease, Parkinson’s disease, or certain cancers.
Dependent Claims:
- Variations of the compound where specific R groups are altered.
- Specific formulations, for example, oral tablets or injectable solutions.
- Methods involving specific dosing regimens or treatment durations.
What is the patent landscape surrounding KR102421388?
Domestic and International Patent Activity
South Korea’s pharmaceutical patent landscape exhibits moderate activity regarding compounds similar to KR102421388:
-
Pre-existing Patents: Several patents prior to 2020 in South Korea and worldwide relate to similar chemical classes, especially in the treatment of neurodegenerative diseases and cancers.
-
Key Competitors: Entities like Hanmi Pharmaceutical, LG Chem, and international firms hold patents on related compounds and formulations, particularly in Asia, the US, and Europe.
Patent Family and Priority Dates
- Priority filing: Several related patents originated from filings in 2018–2019, with patent KR102421388 filed in 2021.
- Patent family: The applicant maintains patent families in China, Japan, and Europe, indicating global strategic protection.
Patentability and Freedom-to-Operate (FTO)
- The novelty appears grounded in specific substituents and methods of treatment.
- Prior art searches reveal similar compounds, but the particular structure claimed differs in key substitution patterns.
- FTO analysis indicates potential freedom-to-operate for formulations and methods, granted that no overlapping active compounds are patented in the territory.
Legal Status and Expiry Timeline
- The patent application was filed in 2021, with an expected expiry date around 2041, assuming a standard 20-year term from filing.
- No oppositions or legal challenges are reported as of Q1 2023; the patent is enforceable.
Key comparative insights
| Aspect |
KR102421388 |
Similar Patents |
Differentiating Factors |
| Chemical scope |
Novel compound class with specific substituents |
Similar compound classes with different substitution patterns |
Unique substitution at R1 and R2, contributing to patentability |
| Application |
Neurodegenerative and oncologic diseases |
Broader or different disease targets |
Focus on specific indications with supporting data |
| Formulation |
Specific formulation claims |
General formulations |
Sharp focus on oral/injectable forms with stability data |
Summary of patent landscape implications
The patent provides distinct protection for a specific class of compounds and their therapeutic applications. It exists within a landscape of related patents but claims a unique chemical structure and use case, reducing immediate infringement risks. Companies seeking to develop similar compounds or formulations must navigate this intellectual property environment carefully.
Key Takeaways
- The patent covers a specific chemical structure with claims that extend to formulations and methods of treatment.
- The scope is focused on targeted indications, mainly neurodegenerative and cancer therapies.
- The patent landscape involves prior art but maintains novelty through unique substitution patterns.
- The patent term is standard; ongoing R&D and filing strategies in adjacent territories are crucial to maintaining competitive edge.
- Potential licensing opportunities may exist with patent holders for joint development or commercialization.
FAQs
1. Does KR102421388 prevent the development of similar compounds?
It protects the specific compound structure and its uses; development of similar compounds with different structures may not infringe but requires patent clearance.
2. Are there known legal challenges against this patent?
No recorded oppositions or litigations as of Q1 2023.
3. Can this patent be licensed?
Yes, if the patent holder agrees, licensing is possible for further development or commercialization.
4. How does this patent compare to international patents on similar compounds?
It shares similarities with patents filed in China, Japan, and Europe, but claims unique structural features, offering comparable protection in multiple jurisdictions.
5. When will the patent expire?
Expected around 2041, assuming standard patent term.
References
[1] Korean Intellectual Property Office. (2023). Patent KR102421388.
[2] WIPO. (2023). Patent family data for relevant drug patents.
[3] European Patent Office. (2022). Patent family analysis on neurodegenerative compounds.
[4] U.S. Patent and Trademark Office. (2022). Similar compounds in oncology indications.
[5] Hanmi Pharmaceutical. (2022). Portfolio disclosures.
